research LB1681 Risk of merkel cell carcinoma progression after treatment discontinuation in patients with an objective response to anti-PD-(L)1 immunotherapy
In this retrospective study of patients with advanced Merkel cell carcinoma responding to immunotherapy, those treated for 18 months or longer showed better progression-free outcomes compared to shorter treatment durations, indicating potential benefits of extended therapy duration.